Skip to content

Invasive Therapy for Cervicogenic Headache

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN07444684
Enrollment
30
Registered
2005-08-10
Start date
1997-09-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervicogenic headache Signs and Symptoms Headache

Interventions

Radiofrequency neurotomy of the cervical facet joint, eventually followed by a radiofrequency lesion of a cervical dorsal root ganglion versus conservative therapy (local injections with anaesthetic a

Sponsors

University Hospital Maastricht, Pain Centre (The Netherlands)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The study group was recruited from patients with cervicogenic headache (CH) according to the diagnostic criteria of Sjaastad. The other following inclusion criteria had to be fulfilled: 1. Age between 20 and 65 years; chronic cervicogenic headache of more than 2 years' duration 2. An initial visual analogue scale (VAS) score of more than 50 mm during a pain period 3. A significant pain during at least two days per week 4. At least one of the following symptoms on physical examination of the neck: paravertebral tenderness on palpation of the cervical spine and/or positive tender points at specific points indicating the involvement of segmental nerves and/or reduction of range of motion in the cervical spine

Exclusion criteria

Exclusion criteria: Excluded from the study were patients who had previous surgical procedures of the cervical spine; who had coagulation disturbances; who were pregnant; who had multilevel severe degenerative changes; who were diagnosed with post-whiplash syndrome and in whom none of the symptoms on physical examination described above were present.

Design outcomes

Primary

MeasureTime frame
Mean visual analogue scores of pain at 8 weeks, 3-months, 6-months and 1 year

Secondary

MeasureTime frame
Global perceived effect by patient at the above-mentioned timepoints. The number of headache days, the medicine use and the headache intensity during a week were also recorded.

Countries

Netherlands

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026